Regulation of apoptosis reduction in the cisplatin-resistant A431 cell line by Bcl-2 and CPP32

Chemotherapy

Volumn 46, Issue 1, 2000, Pages 69-76

  Mese, Hiroshi ^a   Sasaki, Akira ^a   Alcalde, Rafael E ^a   Nakayama, Shuko ^a   Matsumura, Tomohiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Bax; Bcl 2; Cisplatin resistance; CPP32; p53

Indexed keywords

CASPASE 3; CISPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME LINKED IMMUNOSORBENT ASSAY; GEL ELECTROPHORESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

EID: 0033988637     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000007258     Document Type: Article

References (35)

1. Gately DP, Howell SB: Cellular accumulation of the anticancer agent CDDP: A review. Br J Cancer 1993; 67:1171-1176.
2. Tew KD: Glutathione-associated enzymes in anticanecr drug resistance. Cancer Res 1994:54:4313-4320.
3. Yang YY, Woo ES, Reese CE, Bahnson RR, Saijo N, Lazo JS: Human metallothionein isoform gene expression in cisplatin-sensitive and resistant cells. Mol Pharmacol 1994; 45:453-460.
4. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, Nehme A, Christen RD, Haas M, MacLeod CL. Howell SB: In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997;57:1841-1845.
5. Andrew PA, Howell SB: Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells 1990;2:35-43.
6. Scanlon KJ, Kashani-Sabet M, Tone T, Funato T: Cisplatin resistance in human cancers. Pharmacol Ther 1991;52:385-406.
7. Williams GT: Programmed cell death: Apoptosis and oncogenesis. Cell 1991:65:1097-1098.
8. Eastman A: Activation of programmed cell death by anticancer agents: Cisplatin as a model system. Cancer Cells 1990;2:275-280.
9. Ormerod MG, Orr RM, Peacock JH: The role of apoptosis in cell killing by cisplatin: A flow cytometric study. Br J Cancer 1994;69:93-100.
10. Chen Z, Naito M, Mashima T, Tsuruo T: Activation of actin-cleavable interleukin-1β-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells. Cancer Res 1996;56:5224-5229.
11. Oren M: Relationship of p53 to the control of apoptotic cell death. Cancer Biol 1994;5:221-227.
12. Eliopoulos AG, Kerr D. Herold J, Hodgkins L, Krajewski S, Reed JC, Young LS: The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogene 1995;11:1217-1228.
13. Strasser A, Harris AW, Jack T, Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79: 329-339.
14. Hickman JA: Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992;11:121-139.
15. Miyasita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell 1995;80:293-299.
16. Reed JC: Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;74:1-6.
17. Oltvai ZN, Milliman CL, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-619.
18. Wright SC, Wei QS, Kinder DH, Larrick JW: Biochemical pathways of apoptosis: Nicotinamide adenin dinucleotide-deficient cells are resistant to tumor necrosis factor or UV light activation of the 24-kD apoptotic protease and DNA fragmentation. J Exp Med 1996;183:463-471.
19. Yuan J, Shaham S, Ledoox S, Ellis HM, Horvitz HR: The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1-β-converting enzyme. Cell 1993;75:641-652.
20. Nicholsson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labele M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin TT, Yu VL, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37-43.
21. Martin SJ, Green DR: Protease activation during apoptosis: Death by a thousand cuts? Cell 1995;82:349-352.
22. Mese H, Sasaki A. Alcalde RE, Nakayama S, Matsumura T: Establishment and characterization of cisplatin-resistant human epidermoid carcinoma cell line, A431 cell. Chemotherapy 1998;44:414-420.
23. Miyasita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in human leukemia cell line. Blood 1993;81:151-157.
24. Sorenson CM, Eastman A: Mechanism of cis-diamminedichloroplatinum(II)-induced cytotoxicity: Role of G2 arrest and DNA doublestrand breaks. Cancer Res 1988;48: 4484-4488.
25. Draetta G, Piwnica-Worms H, Morrison D, Druker B, Roberts T, Beach D: Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate. Nature 1988;336: 738-744.
26. Th'ng JPH, Wright PS, Hamaguchi J, Lee MG, Norbury CJ, Nurse P, Bradbury EM: The FT210 cell line is a mouse G2 phase mutant with a temperature-sensitive CDC2 gene product. Cell 1990;63:313-324.
27. Akiyama T, Yoshida T, Tujita T, Shimizu M, Mizukami T, Okabe M, Akinaga S: G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/ Sdil in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997;57:1495-1501.
28. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC: Somatic point mutations in the p53 gene of human tumors and cell lines: Updated compilation. Nucleic Acids Res 1996;24:141-146.
29. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye SB: Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993;55:678-684.
30. Lee JM, Bernstein A: p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993; 90:5742-5746.
31. Wang Y, Szekely L, Okan I, Klein G, Wiman KG: Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993;8:3427-3431.
32. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996;56:556-562.
33. Yuan J, Horvitz HR: The Caenorhabditis elegans genes ced-3 and ced-4 act cell autonomously to cause programmed cell death. Dev Biol 1990;138:33-41.
34. Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL, Koeffler HP: Transactivational and DNA binding abilities of endogenous p53 in p53 mutant cell lines. Oncogene 1994:9:1899-1906.
35. Vogelstein B, Kenneth KW: p53 function and dysfunction. Cell 1992;70:523-526.